The impact of depressive symptoms in early Parkinson disease

Neurology

Volumn 69, Issue 4, 2007, Pages 342-347

  Ravina, B ^a,g   Camicioli, R ^b   Como, P G ^a   Marsh, L ^c   Jankovic, J ^d   Weintraub, D ^e   Elm, J ^f  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^g NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CREATINE; GPI 1485; MINOCYCLINE; UBIDECARENONE;

ADULT; ANALYTIC METHOD; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DEMOGRAPHY; DEPRESSION; FEMALE; GERIATRIC DEPRESSION SCALE; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; SCREENING; UNIFIED PARKINSON DISEASE RATING SCALE;

ACTIVITIES OF DAILY LIVING; AGED; ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; CLINICAL TRIALS, PHASE II; COHORT STUDIES; COMORBIDITY; DEPRESSIVE DISORDER; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; REPRODUCIBILITY OF RESULTS;

EID: 34547639700     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000268695.63392.10     Document Type: Article

References (31)

1. Dooneief G, Mirabello E, Bell K, Marder K, Stern Y, Mayeux R. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 1992;49:305-307.
2. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson's disease. A community-based study. Arch Neurol 1996;53:175-179.
3. Cole SA, Woodard JL, Juncos JL, Kogos JL, Youngstrom EA, Watts RL. Depression and disability in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1996;8:20-25.
4. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Effect of psychiatric and other nonmotor symptoms on disability in Parkinson's disease. J Am Geriatr Soc 2004;52:784-788.
5. Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson RG. A prospective longitudinal study of depression, cognitive decline, and physical impairments in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1992;55:377-382.
6. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 2000;69:308-312.
7. Marsh L, McDonald WM, Cummings J, Ravina B. Provisional diagnostic criteria for depression in Parkinson's disease: report of an NINDS/NIMH Work Group. Mov Disord 2006;21:148-158.
8. Weintraub D, Moberg PJ, Duda JE, Katz IR, Stern MB. Recognition and treatment of depression in Parkinson's disease. J Geriatr Psychiatry Neurol 2003;16:178-183.
9. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002;8:193-197.
10. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66;664-671.
11. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007;68;120-128.
12. Weintraub D, Oehlberg KA, Katz IR, Stern MB. Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. Am J Geriatr Psychiatry 2006;14:169-175.
13. Weintraub D, Saboe K, Stern MB. Effect of age on Geriatric Depression Scale performance in Parkinson's disease. Mov Disord 2007 (in press).
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
15. Beatty WW, Ryder KA, Gontkovsky ST, Scott JG, McSwan KL, Bharucha KJ. Analyzing the subcortical dementia syndrome of Parkinson's disease using the RBANS. Arch Clin Neuropsychol 2003;18:509-520.
16. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 2003;54:363-375.
17. Richard I, Kurlan R. The under-recognition of depression in Parkinson's disease. Neuropsychiatric Disease and Treatment 2006.
18. Katon WJ, Unutzer J, Simon G. Treatment of depression in primary care: where we are, where we can go. Med Care 2004;42:1153-1157.
19. Pinquart M, Duberstein PR, Lyness JM. Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy. Am J Psychiatry 2006;163:1493-1501.
20. Starkstein SE, Petracca G, Chemerinski E, et al. Depression in classic versus akinetic-rigid Parkinson's disease. Mov Disord 1998;13:29-33.
21. Lyness JM, Heo M, Datto CJ, et al. Outcomes of minor and subsyndromal depression among elderly patients in primary care settings. Ann Intern Med 2006;144:496-504.
22. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000;48:938-942.
23. Menza M, Marin H, Kaufman K, Mark M, Lauritano M. Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci 2004;16:315-319.
24. Pintor L, Bailles E, Valldeoriola F, Tolosa E, Marti MJ, de Pablo J. Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode. Gen Hosp Psychiatry 2006;28:59-64.
25. Weintraub D, Taraborelli D, Morales KH, Duda JE, Katz IR, Stern MB. Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study. J Neuropsychiatry Clin Neurosci 2006;18:377-383.
26. Scogin F, Shah A. Screening older adults for depression in primary care settings. Health Psychol 2006;25:675-677.
27. Brown RG, MacCarthy B, Gotham AM, Der GJ, Marsden CD. Depression and disability in Parkinson's disease: a follow-up of 132 cases. Psychol Med 1988;18:49-55.
28. Torack RM, Morris JC. The association of ventral tegmental area histopathology with adult dementia. Arch Neurol 1988;45:497-501.
29. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol 1991;50:743-755.
30. Papapetropoulos S, Ellul J, Argyriou AA, Chroni E, Lekka NP. The effect of depression on motor function and disease severity of Parkinson's disease. Clin Neurol Neurosurg 2006;108:465-469.
31. Kuhn W, Heye N, Muller T, et al. The motor performance test series in Parkinson's disease is influenced by depression. J Neural Transm 1996;103:349-354.